Latest OncoZenge News & Updates

See the latest news and media coverage for OncoZenge. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
OncoZenge

Developer of lozenges for oral mucositis pain relief

oncozenge.se
Headquarters
Stockholm, Sweden
Company type
Public company
Number of employees
4–10
Industry
Pharmaceuticals

Last updated

Latest news about OncoZenge

In short: OncoZenge advanced its Phase III trial for BupiZenge and secured strategic funding while managing multiple payment deadline extensions.

Company announcements

OncoZenge

OncoZenge resolves directed share issue to Sichuan Yangtian

The fourth tranche of SEK 15.1 million follows European Phase III approval for BupiZenge.

Unlock all announcements with a

Media coverage

Investing.com

Should you buy, sell, or hold ONCOZ?

The consensus rating for Oncozenge AB is "Strong Buy", based on insights from 1 analyst. 0 analysts recommend buying the stock, 0 suggest selling and 0...

FinanzNachrichten.de

OncoZenge AB: OncoZenge Receives European Regulatory Approval to Start Pivotal Phase III Trial of BupiZenge

OncoZenge AB (publ) ("OncoZenge" or "the Company"), a clinical-stage company developing an innovative treatment for oral pain in cancer supportive care, today announced that it...

Unlock all articles with a

Never miss news about OncoZenge

Track OncoZenge and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.